[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial

被引：0
|
作者：
H. Adams
E. M. W. van de Garde
D. J. Vugts
J. C. Grutters
Wim. J.G. Oyen
R. G. Keijsers
机构：
[1] Groene Hart Hospital,Department of Nuclear Medicine
[2] ILD Center of Excellence,Department of Pulmonology
[3] St. Antonius Hospital,Department of Clinical Pharmacy
[4] St Antonius Hospital,Division of Pharmacoepidemiology and Clinical Pharmacology
[5] Utrecht University,Department of Radiology and Nuclear Medicine, Amsterdam UMC
[6] Vrije Universiteit Amsterdam,Division of Heart & Lung
[7] University Medical Center Utrecht,Department of Biomedicals Sciences and Humanitas Clinical and Research Center, Department of Nuclear Medicine
[8] Humanitas University,Department of Radiology and Nuclear Medicine
[9] Rijnstate Hospital,Department of Radiology and Nuclear Medicine
[10] Radboud University Medical Center,Department of Nuclear Medicine
[11] St. Antonius Hospital,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Interstitial lung disease; CD20; Rituximab; 89Zr-rituximab; Immuno PET; PET-CT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1929 / 1939
页数：10
相关论文
共 33 条
  • [1] [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial
    Adams, H.
    van de Garde, E. M. W.
    Vugts, D. J.
    Grutters, J. C.
    Oyen, Wim. J. G.
    Keijsers, R. G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (07) : 1929 - 1939
  • [2] [89Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study
    Adams, Human
    van de Garde, Ewoudt M. W.
    van Moorsel, Coline H. M.
    Vugts, Danielle J.
    van Dongen, Guus A. M. S.
    Grutters, Jan C.
    Keijsers, Ruth G.
    [J]. AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 9 (06): : 296 - 308
  • [3] Immuno-PET Imaging of the GFR-2 Expression in Prostate Cancer Using 89Zr labeled Ramucirumab
    Li, Miao
    Chen, Weiyu
    Jiang, Dawei
    Engle, Jonathan
    Cao, Tianye
    Cai, Weibo
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [4] Immuno-PET and Targeted a-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
    Watabe, Tadashi
    Kabayama, Kazuya
    Naka, Sadahiro
    Yamamoto, Ryuku
    Kaneda, Kazuko
    Serada, Satoshi
    Ooe, Kazuhiro
    Toyoshima, Atsushi
    Wang, Yang
    Haba, Hiromitsu
    Kurimoto, Kenta
    Kobayashi, Takanori
    Shimosegawa, Eku
    Tomiyama, Noriyuki
    Fukase, Koichi
    Naka, Tetsuji
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (12) : 1949 - 1955
  • [5] Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
    Annie Ogasawara
    James R. Kiefer
    Herman Gill
    Eugene Chiang
    Shravan Sriraman
    Gregory Z. Ferl
    James Ziai
    Sandra Sanabria Bohorquez
    Sebastian Guelman
    Xiangdan Wang
    Jihong Yang
    Minh Michael Phan
    Van Nguyen
    Shan Chung
    Christine Yu
    Jeff Tinianow
    Stijn Jan Hein Waaijer
    Alex De Crespigny
    Jan Marik
    C. Andrew Boswell
    Tanja Zabka
    Karin Staflin
    Simon-Peter Williams
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 287 - 301
  • [6] [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model
    Kirstin A. Zettlitz
    Wen-Ting K. Tsai
    Scott M. Knowles
    Felix B. Salazar
    Naoko Kobayashi
    Robert E. Reiter
    Anna M. Wu
    [J]. Molecular Imaging and Biology, 2020, 22 : 367 - 376
  • [7] [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model
    Zettlitz, Kirstin A.
    Tsai, Wen-Ting K.
    Knowles, Scott M.
    Salazar, Felix B.
    Kobayashi, Naoko
    Reiter, Robert E.
    Wu, Anna M.
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2020, 22 (02) : 367 - 376
  • [8] Correction to: Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy
    Ogasawara, Annie
    Kiefer, James R.
    Gill, Herman
    Chiang, Eugene
    Sriraman, Shravan
    Ferl, Gregory Z.
    Ziai, James
    Bohorquez, Sandra Sanabria
    Guelman, Sebastian
    Wang, Xiangdan
    Yang, Jihong
    Phan, Minh Michael
    Nguyen, Van
    Chung, Shan
    Yu, Christine
    Tinianow, Jeff
    Waaijer, Stijn Jan Hein
    De Crespigny, Alex
    Marik, Jan
    Boswell, C. Andrew
    Zabka, Tanja
    Staflin, Karin
    Williams, Simon-Peter
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (02) : 631 - 631
  • [9] Preclinical development of a 89Zr-labeled human antibody as a novel immuno-PET agent for noninvasive cancer detection and monitoring response to treatment
    Singh, Abhay Kumar
    Lewis, Calvin D.
    Boas, Cristian Awv
    Diebolder, Philipp
    Jethva, Prashant N.
    Rhee, Aaron
    Song, Jong Hee
    Goo, Young Ah
    Li, Shunqiang
    Liu, Yongjian
    Rogers, Buck
    Kapoor, Vaishali
    Hallahan, Dennis E.
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [10] Immuno-PET/CT imaging with 89Zr-rituximab as a prelude for radioimmunotherapy with 90Y-rituximab in patients with relapsed CD20+B-cell non-Hodgkin's lymphoma
    Muylle, K.
    Azerad, M. A.
    Perk, L. R.
    Meuleman, N.
    Delrieu, V.
    Ghanem, G.
    Bourgeois, P.
    Vanderlinden, B.
    van Dongen, G. A.
    Flamen, P.
    Bron, D.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 179 - 180
1234